Warning letterPosted December 9, 2025

FDA warning letter to Lux Therapeutics LLC dba Ponya Therapeutics LLC

Unapproved New Drug/Unlicensed Biological Product/Biologics License Application (BLA)

FDA's record ↗

FDA posted a warning letter to Lux Therapeutics LLC dba Ponya Therapeutics LLC on December 9, 2025; the letter is dated November 25, 2025. Subject: Unapproved New Drug/Unlicensed Biological Product/Biologics License Application (BLA). Issuing office: Office of Compliance and Biologics Quality.

On the record

Company
Lux Therapeutics LLC dba Ponya Therapeutics LLC
Subject
Unapproved New Drug/Unlicensed Biological Product/Biologics License Application (BLA)
Issuing office
Office of Compliance and Biologics Quality
Letter dated
2025-11-25
Posted by FDA
2025-12-09
Source
FDA warning letters ↗

CFR cited

The record cites 2 sections of 21 CFR Part 1271.

The full record

An account shows the violations FDA described and each CFR section it cited.

What a warning letter is

A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.

More

Watch Lux Therapeutics LLC dba Ponya Therapeutics LLC

A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.

From FDA warning letters. The record may have changed since it was read.

Approve Suite is not affiliated with FDA, or with Lux Therapeutics LLC dba Ponya Therapeutics LLC.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.